| Nov 22 |
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares
|
| Nov 15 |
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer
|
| Nov 14 |
SeaStar Medical Holding reports Q3 results
|
| Nov 13 |
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
|
| Nov 6 |
FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis
|
| Nov 1 |
Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial
|
| Oct 31 |
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
|
| Oct 9 |
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit
|
| Oct 8 |
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
|
| Sep 4 |
SeaStar Medical retires all long-term debt
|
